Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma

NCT ID: NCT06270576

Last Updated: 2024-02-21

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-04-30
• Study Completion Date: 2028-06-30

Brief Summary

A phase I clinical research study aimed at determining mechanisms that regulate airway mucosal inflammation in asthma endotypes using intranasal administration of endotoxin (lipopolysaccharide from E. coli) in healthy controls and subjects diagnosed with asthma.

Detailed Description

Patients with severe asthma can be broadly classified into three endotypes (T2, T1, and T17) based on inflammatory cell and cytokine profiles. Within these endotypes, many patients have high levels of neutrophils in the airways and mucosal epithelium. Our preliminary data suggest that neutrophils in the airways and blood of patients with severe asthma are heterogenous and that subsets exist. The nature of these subsets appears to differ between T2, T1, and T17 asthma endotypes.

In order to advance the field and determine the mechanisms that underpin severe neutrophilic asthma, investigators plan to longitudinally assess transcriptional profiles and functional properties of neutrophil subsets that migrate to the nasal cavity following exposure to a standardized dose of Clinical Reference Center endotoxin (IRB#HS-3131-528, IND 018580).

Investigators will recruit 15 subjects of each asthma endotype (45 total participants with asthma) and 15 healthy controls. LPS will be used to elicit migration of neutrophils into the nasal cavities. Neutrophils will be isolated from the nasal cavities using both nasal lavage and nasal brushes 20 minutes, 1 day and 3 days after endotoxin challenge. Neutrophil biology will be assessed using single-cell RNAseq and ex vivo functional assays.

Conditions

Asthma; Eosinophilic; Asthma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Asthma Group

Subjects diagnosed with one of the three asthma endotypes being studied (T2, T1, or T17).

Group Type: ACTIVE_COMPARATOR

Lipopolysaccharides

Intervention Type: DRUG

LPS aka endotoxin is a component of bacterial cell walls and is ubiquitous in the environment. It is found in pet dander, house dust and environmental dusts and has been heavily studied in asthma.

Control Group

Subjects with no diagnosis of asthma or other respiratory disease and are deemed healthy.

Group Type: ACTIVE_COMPARATOR

Lipopolysaccharides

Intervention Type: DRUG

LPS aka endotoxin is a component of bacterial cell walls and is ubiquitous in the environment. It is found in pet dander, house dust and environmental dusts and has been heavily studied in asthma.

Interventions

Lipopolysaccharides

LPS aka endotoxin is a component of bacterial cell walls and is ubiquitous in the environment. It is found in pet dander, house dust and environmental dusts and has been heavily studied in asthma.

Intervention Type: DRUG

Other Intervention Names

Endotoxin; LPS; Clinical reference center lipopolysaccharide; LPS E. Coli O:113

Eligibility Criteria

Inclusion Criteria

• Participants will have asthma diagnosed by a health care provider. Healthy controls are individuals without asthma.
• Written informed consent

Exclusion Criteria

• Current or recent illness (in the past 4 weeks)
• Recent asthma exacerbation (past 4 weeks)
• History of nasal perforation or nasal surgery
• Nasal polyposis
• Presence or prior history of cardiac or systemic disease
• Bleeding disorder, use of systemic anticoagulants, or antiplatelet therapy
• Immunocompromised state (HIV, immunoglobulin deficiency, systemic immunosuppressants excluding corticosteroids)
• Use of tobacco or marijuana in the past 2 months or greater than a 10 pack-year smoking history
• Currently pregnant or breastfeeding

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Jewish Health

OTHER

Sponsor Role: lead

Responsible Party

William Janssen, MD

Section Head of Critical Care, Professor of Medicine, Principle Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

National Jewish Health

Denver, Colorado, United States

Countries

United States

Facility Contacts

William J Janssen, MD

Role: primary

303-398-1366

Olivia M VerBurg, BA

Role: backup

303-398-1201

Other Identifiers

HS3131

Identifier Type: -

Identifier Source: org_study_id